Lipoprotein Metabolism and Renal Failure

American Journal of Kidney Diseases

Volumn 21, Issue 6, 1993, Pages 573-592

  Attman, Per Ola ^a,b   Samuelsson, Ola ^a,b   Alaupovic, Petar ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

apolipoproteins; atherosclerosis; cardiovascular disease; chronic renal failure; dialysis; Lipoproteins; metabolism

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; DIALYSIS; DYSLIPOPROTEINEMIA; HUMAN; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; REVIEW; UREMIA;

EID: 0027288724     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)80030-8     Document Type: Article

References (202)

1. Lipid abnormalities in renal disease
2. Lipid abnormalities in chronic renal insufficiency
3. Lipid abnormalities in uremia, dialysis and transplantation
4. The uremic dyslipoproteinemia: Its characteristics and relations to clinical factors
5. Hyperlipidemia and renal disease
6. Hyperlipoproteinemia in chronic renal failure: Pathophysiological and therapeutic aspects
7. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia—Relation to renal function and dialysis
8. Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis
9. Lipoproteins and apolipoproteins during the progression of chronic renal disease
10. Hypertriglyceridemia in patients with chronic renal insufficiency
11. Further definition of lipid-lipoprotein abnormalities in children with various degrees of chronic renal insufficiency
12. Lipid and carbohydrate metabolism in uraemia
13. Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: A comparison with type IV hyperlipoproteinemic patients
14. Cholesterol and lipid disturbances in renal disease. The natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis
15. Effects of chronic uremia, hemodialysis and renal transplantation on plasma lipids and lipoproteins in man
16. The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins
17. Prevalence of serum lipid abnormalities in chronic hemodialysis
18. A longitudinal study of lipid abnormalities in renal failure
19. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis
20. Lipoprotein abnormalities in chronic hemodialysis patients
21. Effects of long-term haemodialysis on lipid, lipoprotein and apolipoprotein levels of black patients with chronic renal failure
22. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure
23. Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis
24. Hyperlipidemia after organ transplantation
25. Lipoprotein metabolism and the role of apolipoprotein as metabolic programmers
26. Apolipoprotein genetic variation and human disease
27. Preparative ultracentrifugation and analytic ultracentrifugation of plasma lipoproteins
28. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoAand ApoB-containing lipoprotein families
29. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism
30. Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase
31. Modulation of lipoprotein lipase activity by apolipoproteins
32. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of betaVLDL to low density lipoprotein receptor-related protein
33. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
34. Regulation of plasma cholesterol by lipoprotein receptors
35. Functional activities of hepatic lipoprotein receptors
36. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein
37. High density lipoprotein metabolism
38. The plasma lecithin-cholesterol acyltransferase reaction
39. Plasma lipid transfer proteins
40. Lipoprotein subspecies and risk of coronary disease
41. Abnormal concentrations of CII, CIII and E apolipoproteins among apolipoprotein B-containing, B-free, and A-1-containing lipoprotein particles in hemodialysis patients
42. Serum apolipoprotein profile of patients with chronic renal failure
43. Hypertriglyceridemia: A metabolic consequence of chronic renal failure
44. Racial differences in plasma high-density lipoproteins in patients receiving hemodialysis
45. Apoprotein A-I and high density lipoprotein subfractions in patients with chronic renal failure receiving hemodialysis
46. Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients
47. Selective deficiency of hepatic triglyceride lipase in uremic patients
48. Apolipoprotein and lipid abnormalities in uremic children on hemodialysis
49. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis
50. Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment
51. Lipoprotein and apoprotein levels in different types of dialysis
52. Lipids and apolipoproteins change during progression of chronic renal failure
53. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: Relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I
54. Quantitative and qualitative changes of apolipoprotein AI-containing lipoproteins in patients on continuous ambulatory peritoneal dialysis
55. Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis
56. High-density lipoprotein cholesterol subfractions in chronic uremia
57. Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease
58. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis
59. Impaired metabolism of high density lipoprotein in uremic patients
60. Lipid and apolipoprotein profile in diabetic chronic renal failure
61. Presence of ApoB-48, and relative ApoC-II deficiency and ApoC-III enrichment in uremic very-low density lipoproteins
62. The compositional abnormalities in lipoprotein density classes of patients with chronic renal failure (CRF)
63. Apolipoprotein B-containing lipoprotein particles in progressive renal insufficiency
64. David Rubenstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins
65. Abnormalities of lipoprotein composition in renal insufficiency
66. Apolipoprotein B turnover in dialysis patients: Its relationship to pathogenesis of hyperlipidemia
67. Accumulation of lipoprotein remnants in patients with chronic renal failure
68. Increased lipoproteinremnant formation in chronic renal failure
69. Increased frequency of late pre-β lipoproteins (Lpβ) in isolated serum very low density lipoproteins in uremia
70. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients
71. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis. The role of postheparin lipases in the metabolism of high-density lipoprotein subfractions
72. Human serum lipoproteins and their interrelationships
73. Fat transport in lipoproteins: An integrated approach to mechanism and disorders
74. The plasma lipoproteins
75. Heterogeneity of very-low density lipoprotein metabolism in hyperlipidemic subjects
76. Metabolic heterogeneity in very low-density lipoproteins
77. Kinetics of LDL subfractions
78. In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I, A-II
79. Profiles of apolipoproteins and apolipoprotein Bcontaining lipoprotein particles in dyslipoproteinemias
80. Apolipoprotein A-containing lipoprotein particles: Physiological role, quantification, and clinical significance
81. Separation of ApoA- and ApoBcontaining lipoproteins of human plasma by affinity chromatography on concanavalin A
82. Separation and identification of apoB-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias
83. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-111:E lipoproteins with the low density lipoprotein receptor of HeLa cells
84. ApoBcontaining lipoprotein particles as risk factors for coronary artery disease
85. The lipoprotein family concept and its clinical significance
86. Apolipoprotein AI-containing lipoproteins in coronary artery disease
87. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease
88. A multicenter comparison of the effect of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
89. Effect of lovastatin on apoA- and ApoB-containing lipoprotein families—A report from the Mevacor Atherosclerosis Regression Study
90. Increased concentrations of apoB-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure
91. Evaluation of apolipoprotein A-1-containing particles in chronic renal failure patients undergoing hemodialysis
92. A new serum type system in man: The Lp system
93. Lipoprotein (a): Heterogeneity and biological relevance
94. Lipoprotein (a). Clinical approach to a unique atherogenic lipoprotein
95. Association of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography
96. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients
97. Increased Lp(a) concentrations in chronic renal failure
98. Serum lipoprotein (a) in patients with different degrees of chronic renal failure before and after initiation of dialysis therapy
99. Increased serum apolipoprotein (a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis
100. Lipoprotein (a) levels in chronic renal disease states, dialysis and transplantation
101. Lipoprotein (a) and the cardiovascular risk of end-stage renal disease
102. High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis
103. Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism
104. Lipid and lipoprotein (a) concentrations in renal transplant patients
105. Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD
106. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients
107. Defective triglyceride removal in lipemia associated with peritoneal dialysis and hemodialysis
108. Reduction of plasma triglycerides by diet in subjects with chronic renal failure
109. Hyperlipidemia in renal failure: Studies of plasma lipoproteins, hepatic triglyceride production and tissue lipoprotein lipase in a chronically uremic rat model
110. Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat
111. Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia
112. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: The relative pathogenetic roles of triglyceride production and triglyceride removal
113. Factors of increase in serum triglyceride-rich lipoproteins in uremic rats
114. Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism
115. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia
116. Lecithin-cholesterol acyl transferase (LCAT) activity in chronic uremia
117. Postheparin plasma triglyceride lipase in chronic hemodialysis: Evidence for a role for hepatic lipase in lipoprotein metabolism
118. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis
119. Effect of protein-reduced diet on plasma lipids, apolipoproteins and lipolytic activities in patients with chronic renal failure
120. Plasma lipoprotein and lecithin: cholesterol acyltransferase distribution in patients on dialysis
121. Correction by insulin of disturbed TG-rich LP metabolism in rats with chronic renal failure
122. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure
123. Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis
124. Lipid abnormalities, renal failure and parathyroid hormone
125. Excress parathyroid hormone adversely affects lipid metabolism in chronic renal failure
126. Glucose and insulin metabolism in uremia
127. Treatment of uremic hypertriglyceridemia with bezafibrate
128. Early changes of plasma lipid status and glucose tolerance during the course of chronic renal failure
129. Defect in cholesterol transport in patients receiving maintenance hemodialysis
130. Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure
131. Increased lipid peroxidation in patients on maintenance hemodialysis
132. Serum uremic factors inhibit apolipoprotein (apo)A-1 synthesis in human hepatocytes
133. The effect of renal failure and hemodialysis on the concentration of free apolipoprotein A-I in serum and in the implications for the catabolism of high-density lipoproteins
134. Influence of end-stage renal failure on concentrations of free apolipoprotein A-I in serum
135. Apolipoprotein E synthesis in human kidney, adrenal gland and liver
136. Chronic renal failure: Pathophysiology
137. Lipid abnormalities in cyclosporine-treated renal transplant recipients
138. Effect of protein-restricted diet on serum lipids and atherosclerosis risk factors in patients with chronic renal failure
139. Three-year lipoprotein (LP) study in hemodialysis (HD) and CAPD patients
140. Blood lipid profile in hemodialysis patients treated with human erythropoietin
141. National registry of long-term dialysis patients
142. Accelerated atherosclerosis in prolonged maintenance hemodialysis
143. Smoking, hypertension and mortality in a maintenance dialysis population
144. Arterial calcification and pathology in uremic patients undergoing dialysis
145. The role of hypertension in hemodialysis associated atherosclerosis
146. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease
147. Should hyperlipidemia of renal failure be treated?
148. Cardiovascular complications in renal failure
149. CHD risk factors. A Framingham study update
150. Update on the pathogenesis of atherosclerosis
151. Cardiovascular risk factors in chronic renal failure and hemodialysis populations
152. Management of hyperlipidemia of kidney disease
153. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias
154. Blood lipids, lipid-related measures, and the risk of atherosclerotic cardiovascular disease
155. The status of hypertriglyceridemia as a risk factor for coronary heart disease
156. Plasma triglycerides and coronary heart disease
157. Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
158. A fresh look at the atherogenic remnant hypothesis
159. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts
160. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
161. Triglyceride-rich lipoproteins and their role in atherogenesis
162. The progression of renal disease
163. Hypertension and renal diseases
164. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease
165. Lipids and the progression of renal disease
166. Relationship between serum cholesterol and diabetic nephropathy
167. Lipids and progressive kidney disease
168. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure
169. Lipids in the progression of chronic renal failure
170. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency
171. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis
172. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
173. Possible association between an abnormal low density lipoprotein and nephropathy in lecithin cholesterol acyltransferase deficiency
174. Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidneys of patients with hepatorenal syndrome
175. Renal lipidoses: A review
176. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy
177. Hyperlipidemia and progressive renal disease
178. Glomerular lipidosis in intercapillary glomerulosclerosis
179. Significance of renal hyaline arteriosclerosis in focal segmental glomerulosclerosis
180. Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: A role for lipoprotein glomerulopathy
181. Intraglomerular lipid deposition in routine biopsies
182. Receptor mediated uptake of ApoB and ApoErich lipoproteins by human glomerular cells
183. Lipids and the kidney
184. Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies
185. Cholestyramine resin ameliorates chronic aminonucleoside nephrotis
186. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
187. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure
188. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
189. Contrasting effects of lovastatin and enalapril on glomerular injury in Dahl salt-sensitive rats
190. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis
191. Mechanisms of the interaction of hypertension and hypercholesterolemia in atherogenesis: The effects of antihypertensive agents
192. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipemic hemodialysis patients
193. Carnitine metabolism in chronic renal failure
194. Carnitine abnormalities in patients with renal insufficiency
195. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects
196. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients
197. Metabolic parameters: How important are pharmacologically-induced changes?
198. The benefits of β-blockade at the time of myocardial infarction
199. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration
200. Is the aggressive management of hyperlipidemias in nephrotic syndrome mandatory?
201. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate density lipoproteins, in patients with chronic renal failure receiving hemodialysis
202. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis